Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0770 Name of the Signatory :- Upen ShahDesignation :- Company Secretary and Compliance Officer Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0770 Name of the Signatory :- Upen ShahDesignation :- Company Secretary and Compliance Officer Joint Half Yearly Compliance Certificate From The Company And RTA.
Joint Half Yearly Compliance Certificate from the Company and RTA. Certificate From A Practicing Company Secretary For The Half Year Ended On September 30, 2018.
Certificate from a Practicing Company Secretary for the half year ended on September 30, 2018. Company news: Zydus Cadila
Zydus Cadila has received the final approval from the USFDA to market exemestane tablets 25 mg. It will be manufactured at the group's formulations ma Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Exemestane Tablets Announcement under Regulation 30 (LODR)-Press Release / Media Release
We hereby inform that the Company's Biologics manufacturing facility (Zydus Biologics) located at the Zydus Biotech Park in Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA signifying the successful closure of the audit. The plant had completed the USFDA audit from 14th August to 24th August 2018 with Zero 483 observations. Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Regulations')
As per the Disclosure made by the Company vide its letter dated August 13, 2018 the Company was to complete acquisition of 51% stake in the Equity Share Capital of Windlas Healthcare Private Limited by the end of September, 2018. We hereby disclose that certain condition precedents are still under completion and thus the Company expects the transaction closing to take place on or before October 31, 2018. Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR) - Press Release - Zydus Receives final approval from USFDA for Desoximetasone Cream USP. Cadila Healthcare plans to launch 50 products in US market in FY19
Of over 140 products in pipeline, at least 10 are para IV filings